Search

everythinglearnresearchcommunity

for

Search:↓

Serum DHT levels and their variations when using dutasteride for hair loss treatment.

The progress of Phase I of HMI-115, a potential hair loss treatment, which consists of Minoxidil, finasteride, and RU58841. The estimated completion date is June.

The conversation is about someone experiencing hair regrowth using Minoxidil and Dutasteride, along with other treatments. They report their hairline is improving and their forehead appears smaller.

The user experienced significant hair regrowth using a combination of minoxidil, finasteride (later switching to dutasteride), and tretinoin over two years. They noticed regrowth almost immediately, with no major initial shedding phase, and reported recession and diffuse hair loss patterns.

The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.

The conversation discusses using P5P (Vitamin B6) supplements to reduce elevated Prolactin levels and concerns about its potential effect on increasing DHT levels. The user is not currently using finasteride or any anti-androgens.

Follicusan DP is discussed as a potential alternative to Minoxidil without side effects, but information is scarce. It is noted to be of German origin and details on its mechanism are limited.

The relative strength of Pyrilutamide compared to RU58841 in terms of androgen receptor binding affinity. It has been noted that Pyrilutamide is 4x stronger than RU58841, with a higher binding affinity than DHT itself.

A user proposed genetically engineering scalp stem cells to stop androgen receptors from causing hair loss. Others discussed the feasibility, existing research, and potential issues with this approach, including targeting the correct cells and unintended effects.

A user shared their hair regrowth progress using Dutasteride, topical Minoxidil, Spironolactone, and Estradiol Valerate injections as part of hormone replacement therapy for transitioning. They experienced significant hair improvement and personal satisfaction but caution against this approach for non-transitioning individuals due to irreversible changes.

Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.

User celebrates 2-year anniversary of 2500 FUE hair transplant procedure and worries about future hair loss. Others compliment the results and suggest using Dut and Min to maintain hair.

The user is taking 2.5 mg dutasteride and 5% minoxidil but is not seeing hair regrowth, and is considering adding RU58841. They are experiencing fatigue and low MCV/MCH, possibly related to dutasteride, and are advised to be patient, consider microneedling, and check for iron deficiency.

The user switched from finasteride to 0.5mg oral dutasteride and added 2.5mg oral minoxidil, along with occasional microneedling, to improve hair regrowth. They reported no side effects and are hopeful for continued progress, especially in the temple area.

High dose niacin (1000mg daily) seems to have halted hair loss but did not regrow lost hair. The user plans to continue due to additional benefits like lower stress and higher good cholesterol.

The hair transplant at Eugenix in New Delhi resulted in poor density and texture, with only about 2,500 grafts surviving out of 4,500. The user is considering holding the clinic accountable and exploring options like shaving, using hair fibers, or seeking another transplant.

A natural sugar called 2dDR may stimulate hair growth and is comparable to minoxidil, but it's not widely available for purchase. Concerns about minoxidil's safety for pets were discussed, with some users seeking alternatives.

How diffuse unpatterned alopecia (DUPA) is not an invitation to self-diagnose oneself with aggressive AGA and that seeking a specialized dermatologist may help people experiencing hair loss. Treatment options discussed include topical clobetasol propionate, oral minoxidil, and discontinuing finasteride.

Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. Users share experiences and support, mentioning that many people face hair thinning.

The conversation is about hair loss and the use of specific treatments like minoxidil, finasteride, and RU58841.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.

The conversation discusses using finasteride or dutasteride to reduce DHT, CosmeRNA to target androgen receptors, and Minoxidil as a vasodilator for hair growth. The regimen aims to maintain hair by addressing DHT-AR ratio and continuous Minoxidil use.

People are discussing hair loss treatments and expressing hope for future hair cloning. Some mention using Minoxidil, finasteride, and RU58841.

A user suggests making a potent sulforaphane topical to degrade DHT and promote hair growth. Another user notes that sulforaphane's low molecular weight might also lower systemic DHT.

Dustaride doesn't require avoiding any vitamins, but checking vitamin D levels and supplementing if deficient is suggested. Hair vitamins are generally unnecessary unless there's a deficiency.

A 28 year old using a hair loss prevention protocol to restore thinning hair, which includes finasteride, dutasteride, minoxidil, stemoxydine, alopecin, nizoral shampoo and microneedling; the user is now adding pyrilutamide solution to the regimen with the hope of improving their results. RU58841 was also ordered but not yet used.

The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It suggests that affordable genetic therapy could be the ultimate solution.

The conversation is about the release of a new phase 3 clinical trial for a year and questioning if the results of the 6-month clinical trials will be shown this quarter. The specific treatment discussed is Pyrilutamide.

A woman experiencing hormonal hair loss is on dutasteride and bicalutamide, which initially improved her hair, but she is now experiencing a second shedding phase with significant short hair loss. Despite normal hormone levels and no deficiencies, she is unsure if this shedding is normal and seeks advice.

Elevated PGD2 levels in bald scalp tissue may contribute to hair loss, and treatments like castor oil, finasteride, and minoxidil are discussed as potential solutions. Some users explore alternatives like oral castor oil and cetirizine for those who cannot use finasteride.